Review
Open access
Sep 2026
Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.
BACKGROUND Fibromyalgia is a chronic disorder characterised by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction. Evidence suggests pathogenic IgG autoantibodies might contribute to severe symptoms. Rozanolixizumab reduces IgG concentration by targeting the neonatal Fc receptor. This study evaluat...
Andreas Goebel, P. Meisner, Gustaf Rydevik et al.
· The Lancet Rheumatology · 0 citations